ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

DCT Board Approves Phase 2/3 Studies Of LAK-IL-2

February 14, 1986

Pediatric Oncology Groups Plan To Merge, Citing Greater Cost Efficiencies, Leverage

August 7, 1998

Heavy Smokers And Drinkers Have Different Brain Chemistry

May 30, 2003

ACS Probably Will Accept Hammer’s Offer On Matching Funds For Survey

February 3, 1984

AHCPR Funds Centers to Review Practice

July 4, 1997

Spending Bill Could Give 15% Raise To NIH; Gimmicks Complicate Picture, Veto Looms

November 5, 1999